VEOZA

This brand name is authorized in Croatia, Estonia, France, Ireland, Lithuania, UK.

Active ingredients

The drug VEOZA contains one active pharmaceutical ingredient (API):

1	Fezolinetant UNII 83VNE45KXX - FEZOLINETANT
	Fezolinetant is a non-hormonal selective neurokinin 3 (NK3) receptor antagonist. It blocks neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron, which is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus.
	Read more about Fezolinetant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VEOZA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G02CX06		G Genito urinary system and sex hormones → G02 Other gynecologicals → G02C Other gynecologicals → G02CX Other gynecologicals
Discover more medicines within G02CX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3056172, 3056183, 3056194
FR	Base de données publique des médicaments	66063738
LT	Valstybinė vaistų kontrolės tarnyba	1098569, 1098570, 1098571, 1099529